Pain processing in the nervous system operates across ascending pathways — which transmit nociceptive signals from tissue to the brain — and descending pathways, which modulate the perceived intensity of those signals. The endocannabinoid system (ECS) is embedded at multiple levels of both pathways, making it an effective pharmacological target for analgesia.
CB1 receptors are densely expressed in the periaqueductal grey (PAG), rostral ventromedial medulla (RVM), dorsal horn of the spinal cord, and primary afferent neurons. When THC or endogenous cannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) bind CB1 receptors, they inhibit adenylyl cyclase, reduce calcium influx at presynaptic terminals, and open inwardly rectifying potassium channels — collectively suppressing neuronal excitability and reducing the transmission of pain signals toward the cortex.
CB2 receptors are found primarily on immune cells — macrophages, microglia, mast cells, and peripheral immune infiltrates at sites of inflammation. CB2 agonism reduces the release of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, decreasing peripheral sensitisation and the neuroinflammation that amplifies chronic pain.
Critically, the ECS is an on-demand system: endocannabinoids are synthesised and released retrograde (post-synaptically back onto pre-synaptic terminals) specifically in response to excessive neuronal firing. In chronic pain states, this homeostatic mechanism becomes dysregulated — endocannabinoid tone is insufficient, and CB1 receptor density in pain-relevant regions decreases. Exogenous cannabinoids from cannabis restore signalling where the body’s own system has been depleted.
CBD adds a complementary anti-inflammatory mechanism: it inhibits cyclooxygenase-2 (COX-2) enzyme activity, the same target as ibuprofen and naproxen. Unlike NSAIDs, CBD also activates the TRPV1 channel (involved in heat and pain detection) at high doses, producing desensitisation. CBD’s interaction with the 5-HT1A serotonin receptor may further contribute to the anxiolytic component of pain relief.
Cannabis evidence varies substantially by pain type. Understanding which conditions have the strongest clinical backing helps set realistic expectations and guides product selection.
| Pain Type | Evidence Level | Best Delivery | Best Ratio | Notes |
|---|---|---|---|---|
| Neuropathic | Strong | Inhaled / Sublingual | High-THC or 1:1 | Best evidence base; works where other analgesics fail |
| Inflammatory | Moderate–Strong | Topical / Oral | High-CBD or 1:1 | CB2 + COX-2 mechanisms; topical for joint inflammation |
| Nociceptive (acute) | Weak | Not recommended | N/A | Insufficient for post-surgical or trauma pain |
| Central Sensitisation | Moderate | Sublingual / Oral | Balanced 1:1 | Fibromyalgia, IBS — reduced central amplification |
| Cancer Pain | Moderate | Oral / Inhaled | High-THC or 1:1 | Also addresses nausea/appetite; opioid-sparing benefit |
The landmark Whiting et al. (2015) JAMA systematic review of 79 RCTs found moderate-quality evidence for cannabinoids in neuropathic pain and cancer pain. A 2018 Cochrane review of 16 RCTs specifically for neuropathic pain found that cannabis produced at least a 30% pain reduction in more patients than placebo, though the number needed to treat (NNT) ranges from 5 to 11 depending on the study population.
Cannabis dosing for pain follows a biphasic dose-response curve: low doses produce analgesic effects, while very high doses can paradoxically increase pain sensitivity (hyperalgesia) and anxiogenesis. This pharmacological reality makes the low-and-slow titration protocol essential.
Microdose (1–2.5 mg THC): Best for daytime functional pain management. Reduces pain awareness without impairing cognition. Particularly effective for central sensitisation conditions where constant low-level ECS modulation is therapeutic. Many patients find this level more useful than higher doses for maintaining daily function.
Therapeutic dose (5–10 mg THC): The analgesic sweet spot for most adult patients. Clinical studies using this range show consistent pain reduction without dose-dependent side effects. Higher doses do not produce proportionally greater analgesia for most pain conditions.
Titration protocol: Start at 1–2.5 mg THC. Hold for 3–5 days before increasing. Increase by 1–2.5 mg increments. Identify the minimum effective dose and maintain it. If pain peaks occur at predictable times (morning stiffness, evening flare), time dosing 30–60 minutes before peak onset. For sleep and night pain, a slightly higher THC dose (10–15 mg) taken 90 minutes before sleep is supported by clinical evidence.
Interaction considerations: Cannabis potentiates opioid analgesia — patients combining both should begin with 50% of their normal THC dose. Cannabis also potentiates benzodiazepines and CNS depressants. CYP3A4 induction by CBD can reduce blood levels of some pain medications including some opioids and NSAIDs.
Delivery method determines onset speed, duration, bioavailability, and dose precision — all critical for pain management. No single method is optimal for all pain scenarios.
| Method | Onset | Duration | Bioavailability | Best For |
|---|---|---|---|---|
| Inhaled (vaporised) | 2–10 min | 1–3 hrs | 25–35% | Breakthrough pain, rapid onset needed |
| Sublingual (tincture) | 15–45 min | 2–4 hrs | 20–30% | Consistent dosing, chronic systemic pain |
| Oral (edibles/capsules) | 45–120 min | 4–8 hrs | 5–20% | Sleep pain, sustained relief, low tolerance |
| Topical (cream/balm) | 20–60 min | 2–4 hrs | Minimal systemic | Joint/muscle pain, no psychoactive effect needed |
| Transdermal patch | 1–2 hrs | 8–12 hrs | ~35% | Sustained systemic delivery, consistent blood levels |
For patients managing chronic neuropathic pain day-to-day, sublingual tinctures offer the best balance of consistent dosing and controlled onset. Inhaled vaporisation serves as rescue medication for breakthrough pain. Topical formulations — particularly those containing CBD and CBG in a full-spectrum carrier — provide targeted relief for arthritis, muscle tension, and localised nerve pain without systemic psychoactive effects.
The United States experiences approximately 80,000 opioid overdose deaths annually. Interest in cannabis as an opioid alternative or adjunct has grown substantially as a result — and the evidence is increasingly supportive of a harm-reduction role.
Lucas (2017) found that patients substituting or augmenting opioids with cannabis reduced their opioid consumption by 64% on average. A separate analysis by Bradford and Bradford (2016) found that states with legal medical cannabis had 14.4% fewer opioid prescriptions under Medicare Part D. Multiple observational studies at dispensary level report between 25% and 97% of patients using cannabis to reduce opioid use, with self-reported success rates above 60%.
| Factor | Cannabis | Opioids | NSAIDs |
|---|---|---|---|
| Primary Mechanism | CB1/CB2 receptor agonism | Mu-opioid receptor agonism | COX-1/COX-2 inhibition |
| Best Evidence (pain) | Neuropathic, chronic | Acute, cancer, post-surgical | Inflammatory, mild–moderate |
| Addiction Risk | ~9% lifetime | 20–30% chronic use | Negligible |
| Organ Toxicity | Minimal (inhaled: lung) | Liver, kidney, endocrine | GI, kidney, cardiovascular |
| Overdose Risk | None (no CB1 in brainstem) | High — respiratory depression | Very low |
| Monthly Cost (US avg.) | $50–$200 (out-of-pocket) | $30–$200 (often covered) | $5–$30 (OTC/Rx) |
Cannabis cannot cause death by overdose: the brainstem regions controlling respiratory function (nucleus tractus solitarius, pre-Bötzinger complex) lack CB1 receptors, making respiratory depression pharmacologically impossible. This contrasts sharply with opioids, where binding mu-receptors in the brainstem is the mechanism of fatal overdose.
Strain selection and product type should be matched to the specific pain mechanism, time of day, and functional requirements. The following guidance reflects both endocannabinoid pharmacology and available clinical and observational data.
Night pain and sleep disruption: High-THC indica-dominant strains (OG Kush, Granddaddy Purple, Northern Lights) are preferred. Take as edible or sublingual tincture 60–90 minutes before sleep. THC reduces REM sleep stages, which can reduce pain-related dream disruption. Target 5–15 mg THC depending on tolerance.
Daytime chronic pain: Balanced 1:1 THC:CBD products (Harlequin, ACDC, Cannatonic) at 5–10 mg THC equivalent. The presence of CBD moderates the psychoactive effect and adds COX-2 anti-inflammatory action without sedation.
Anti-inflammatory (topical): CBD-dominant or full-spectrum topicals applied directly to joints or muscles. CBG (cannabigerol) has emerging evidence for joint inflammation via TRPV1 antagonism. Look for products containing ≥100 mg CBD per ounce for measurable effect.
Terpene guidance for pain:
